Ruxolitinib treatment ameliorates clinical, immunologic, and transcriptomic aberrations in patients with STAT3 gain-of-function disease
Journal of Allergy and Clinical Immunology · 2025
DOI: 10.1016/j.jaci.2024.11.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025. Verfasst von Feyza Bayram Catak und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Allergy and Immunology, Faculty of Medicine, Marmara University, Istanbul, Turkey; Istanbul Jeffrey Modell Diagnostic and Resea…. Hauptthemen laut MEDLINE: Pyrazoles, STAT3 Transcription Factor, Transcriptome, Gain of Function Mutation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Marmara University, Türkiye Bilimsel ve Teknolojik Araştırma Kurumu.
Abstract (Originalsprache)
BACKGROUND: Signal transducer and activator of transcription 3 (STAT3) gain-of-function (GOF) disease presents with lymphoproliferation, autoimmunity, and failure to thrive. Although Janus kinase inhibitors have alleviated symptoms, their effects on disease pathogenesis remain unclear. OBJECTIVE: We prospectively investigated the clinical, immunologic, and transcriptomic responses of 4 patients with STAT3 GOF under long-term ruxolitinib treatment. METHODS: We conducted clinical and immunologic evaluations at baseline and after ruxolitinib treatment at 3, 8, 12, and more than 12 months. Our assessments included measurement of levels of circulating T follicular helper cells, regulatory T cells, and cytokines, as well as proliferation assays. Furthermore, we investigated the transcriptomic changes with treatment and conducted T-cell receptor sequencing. RESULTS: Ruxolitinib achieved substantial control over the clinical manifestations. Posttreatment evaluations demonstrated a notable increase in naive CD4+ and CD8+ T-cell populations, alongside a significant reduction in effector memory T-cell levels. Additionally, there was a decrease in levels of circulating T follicular helper cells and double-negative T cells. Regulatory T-cell percentages and their canonical markers, which were already reduced before treatment, declined further with ruxolitinib. The treatment did not alter the production of IL-4, IL-17A, IL-10, and IFN-γ cytokines by the CD4+ T cells. Importantly, ruxolitinib effectively normalized the previously dysregulated transcriptome profile in PBMCs, bringing it closer to that of healthy controls. This normalization was most striking in the downregulation of STAT3-targeted genes, interferon-related genes, myeloid cell activation, and cytotoxic effector CD8+ T-cell genes, with effects persisting for up to 12 months. Self-reactive T-cell indices based on T-cell receptor repertoire analysis revealed potential autoreactive cell clones in the patient samples. CONCLUSION: Ruxolitinib reversed cellular and transcriptomic signatures, enhancing our understanding of the disease's pathophysiology and highlighting essential immunologic markers for precise monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Allergy and Immunology, Faculty of Medicine, Marmara University, Istanbul, Turkey; Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Istanbul, Turkey; Isil Bera…
- Centre for Cancer Biology, University of South Australia and the SA Pathology, Adelaide, Australia; Data and Bioinformatics Innovation, Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia.
- Division of Pediatric Allergy and Immunology, Antalya Training and Research Hospital, Health Sciences University, Antalya, Turkey.
- Division of Pediatric Allergy and Immunology, Dortcelik Children's Diseases Hospital, Ministry of Health, Bursa, Turkey.
- Division of Pediatric Allergy and Immunology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.
- Department of Biological Sciences, Middle East Technical University, Ankara, Turkey.
Förderung
- Marmara University
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
Zitieren
APA
Bayram Catak, F., Catak, M. C., Babayeva, R., Toubia, J., Warnock, N. I., Celmeli, F., Hafizoglu, D., Yakici, N., Kayaoglu, B., Surucu, N., Yalcin Gungoren, E., Can, S., Yorgun Altunbas, M., Karakus, I. S., Kiykim, A., Orhan, F., Bilgic Eltan, S., Karakoc-Aydiner, E., Ozen, A., …, & Baris, S. (2025). Ruxolitinib treatment ameliorates clinical, immunologic, and transcriptomic aberrations in patients with STAT3 gain-of-function disease. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2024.11.032
Vancouver
Bayram Catak F, Catak MC, Babayeva R, Toubia J, Warnock NI, Celmeli F, et al. Ruxolitinib treatment ameliorates clinical, immunologic, and transcriptomic aberrations in patients with STAT3 gain-of-function disease. Journal of Allergy and Clinical Immunology. 2025. doi:10.1016/j.jaci.2024.11.032
BibTeX
@article{BayramCatak2025,
author = {Bayram Catak, Feyza and Catak, Mehmet Cihangir and Babayeva, Royala and Toubia, John and Warnock, Nicholas I and Celmeli, Fatih and Hafizoglu, Demet and Yakici, Nalan and Kayaoglu, Basak and Surucu, Naz and Yalcin Gungoren, Ezgi and Can, Salim and Yorgun Altunbas, Melek and Karakus, Ibrahim Serhat and Kiykim, Ayca and Orhan, Fazil and Bilgic Eltan, Sevgi and Karakoc-Aydiner, Elif and Ozen, Ahmet and Erman, Baran and Gursel, Mayda and Kok, Chung Hoow and Cildir, Gökhan and Baris, Safa},
title = {Ruxolitinib treatment ameliorates clinical, immunologic, and transcriptomic aberrations in patients with STAT3 gain-of-function disease},
journal = {Journal of Allergy and Clinical Immunology},
year = {2025},
doi = {10.1016/j.jaci.2024.11.032}
}
EUVIMED